Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Bioventus Inc (NASDAQ: BVS) closed at $7.27 down -2.28% from its previous closing price of $7.44. In other words, the price has decreased by -$2.28 from its previous closing price. On the day, 1.12 million shares were traded. BVS stock price reached its highest trading level at $7.44 during the session, while it also had its lowest trading level at $7.091.
Ratios:
For a deeper understanding of Bioventus Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 18.26 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.63. For the most recent quarter (mrq), Quick Ratio is recorded 0.96 and its Current Ratio is at 1.48. In the meantime, Its Debt-to-Equity ratio is 2.24 whereas as Long-Term Debt/Eq ratio is at 1.94.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on July 07, 2025, initiated with a Overweight rating and assigned the stock a target price of $12.
On December 17, 2024, JP Morgan Upgraded its rating to Neutral which previously was Underweight and also upped its target price recommendation from $12 to $13.
Canaccord Genuity Upgraded its Hold to Buy on December 07, 2023, while the target price for the stock was maintained at $7.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 11 ’25 when Singleton Mark Leonard sold 3,875 shares for $7.57 per share. The transaction valued at 29,334 led to the insider holds 141,088 shares of the business.
D’Adamio Anthony sold 2,958 shares of BVS for $22,392 on Apr 11 ’25. The SVP & General Counsel now owns 131,416 shares after completing the transaction at $7.57 per share. On Apr 11 ’25, another insider, CHURCH KATRINA J, who serves as the SVP & Chief Compliance Officer of the company, sold 1,283 shares for $7.57 each. As a result, the insider received 9,712 and left with 55,557 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BVS now has a Market Capitalization of 486307008 and an Enterprise Value of 854111040. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.07 while its Price-to-Book (P/B) ratio in mrq is 3.02. Its current Enterprise Value per Revenue stands at 1.514 whereas that against EBITDA is 13.824.
Stock Price History:
The Beta on a monthly basis for BVS is 0.84, which has changed by -0.24974203 over the last 52 weeks, in comparison to a change of 0.15624678 over the same period for the S&P500. Over the past 52 weeks, BVS has reached a high of $14.38, while it has fallen to a 52-week low of $5.81. The 50-Day Moving Average of the stock is 6.64%, while the 200-Day Moving Average is calculated to be -16.66%.
Shares Statistics:
For the past three months, BVS has traded an average of 448.03K shares per day and 524470 over the past ten days. A total of 66.89M shares are outstanding, with a floating share count of 45.42M. Insiders hold about 32.10% of the company’s shares, while institutions hold 53.00% stake in the company. Shares short for BVS as of 1753920000 were 1799608 with a Short Ratio of 4.02, compared to 1751241600 on 1633086. Therefore, it implies a Short% of Shares Outstanding of 1799608 and a Short% of Float of 6.950000000000001.
Earnings Estimates
A detailed examination of Bioventus Inc (BVS) is currently in progress, with 3.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.22, with high estimates of $0.23 and low estimates of $0.21.
Analysts are recommending an EPS of between $0.65 and $0.64 for the fiscal current year, implying an average EPS of $0.64. EPS for the following year is $0.82, with 3.0 analysts recommending between $0.88 and $0.79.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $137.64M this quarter.It ranges from a high estimate of $140.6M to a low estimate of $136M. As of the current estimate, Bioventus Inc’s year-ago sales were $138.96MFor the next quarter, 4 analysts are estimating revenue of $156.06M. There is a high estimate of $156.6M for the next quarter, whereas the lowest estimate is $155.34M.
A total of 4 analysts have provided revenue estimates for BVS’s current fiscal year. The highest revenue estimate was $568.8M, while the lowest revenue estimate was $563.77M, resulting in an average revenue estimate of $566.06M. In the same quarter a year ago, actual revenue was $573.28MBased on 4 analysts’ estimates, the company’s revenue will be $605.02M in the next fiscal year. The high estimate is $614.74M and the low estimate is $597.02M.
